Arcturus (ARCT) Q1 2026 earnings review
Revenue Evaporates as Arcturus Completes Rare Disease Pivot
Arcturus has completed its strategic transition away from COVID-19 vaccine revenues, relying entirely on its clinical rare disease pipeline. Total revenue reversed sharply, plummeting 93% YoY to just $2.1M as CSL collaboration milestones dried up. However, disciplined cost controls—including a 38% YoY drop in R&D expenses—kept the net loss at $27.0M, allowing management to confirm a cash runway extending beyond Q2 2028. The investment thesis now hinges purely on clinical execution for its Cystic Fibrosis (ARCT-032) and OTC deficiency (ARCT-810) programs.
🐂 Bull Case
With $213.4M in cash and stabilizing operating expenses, the company is fully funded beyond Q2 2028. This removes near-term financing overhangs and covers all major upcoming clinical milestones.
Enrollment for the ARCT-032 12-week Phase 2 study was initiated earlier than expected in Q1 2026, pulling forward the timeline for critical efficacy data in Cystic Fibrosis.
🐻 Bear Case
Collaboration revenue effectively disappeared (down to $0.6M). With the KOSTAIVE COVID-19 vaccine facing a challenging US regulatory path, non-dilutive partner funding has dried up.
While FDA alignment was achieved on the pediatric strategy for ARCT-810, the End of Phase 2 (EOP2) meeting is pushed to H2 2026, stretching the timeline to a pivotal trial.
⚖️ Verdict: ⚪
Neutral. The collapse in revenue was expected due to the strategic pivot, and the company has right-sized its expenses accordingly. However, with no near-term commercial cash flows, the stock is now a pure-play, high-stakes binary bet on the upcoming Phase 2 clinical readouts for ARCT-032 and ARCT-810.
Key Themes
Collaboration Revenue Collapse
The trajectory of collaboration revenue is severely reversing. From a high of $25.5M in 25Q1, it has cratered to just $0.6M in 26Q1. This confirms that the CSL partnership for the KOSTAIVE vaccine is no longer providing meaningful near-term financial support, shifting the entire burden of value creation to the unpartnered clinical pipeline.
ARCT-032 (Cystic Fibrosis) Clinical Acceleration
Clinical execution is accelerating. The company initiated enrollment for its 12-week Phase 2 open-label study of ARCT-032 earlier than initially guided. By evaluating 10 mg dosing over 12 weeks for safety and lung functional improvements (ppFEV1 and LCI), the company is rapidly advancing its inhaled mRNA product innovation toward a definitive efficacy readout.
Aggressive Expense Normalization
Management's strategic restructuring is paying off. Operating expenses are decelerating rapidly. R&D fell 38% YoY to $21.5M, driven by the wind-down of LUNAR-COVID manufacturing. G&A also decreased 16% YoY to $9.5M. This expense control is the primary reason the company can project a cash runway extending past Q2 2028 despite the revenue wipeout.
Navigating Macro Regulatory Hurdles for Pediatric OTC
Navigating the strict FDA macro environment for ultra-rare pediatric diseases is notoriously difficult. A positive Type C meeting provided clear regulatory direction for ARCT-810's pediatric development strategy. While it requires gathering additional exploratory data, the company now has a defined pathway toward a pivotal study for a population where liver transplants are currently the only survival option.
Extended Timelines for ARCT-810 Pivotal Trial
Despite gaining regulatory clarity, the timeline for ARCT-810 is stretching. The End of Phase 2 (EOP2) meeting to finalize pivotal trial alignment is now scheduled for H2 2026. This extended data-gathering phase means a Phase 3 trial initiation is unlikely before late 2026 or early 2027, testing investor patience.
C-Suite Overhaul to Navigate Next Phase
To support its transition to a late-stage rare disease developer, Arcturus brought in Dr. Alan H. Cohen as Chief Medical Officer and Dennis M. Mulroy as Chief Financial Officer. Adding experienced leadership signals a shift from platform validation (vaccines) to strict clinical execution and capital market strategy.
Other KPIs
Stable. The cash balance decreased by $19.4M from the end of 25Q4 ($232.8M). This burn rate perfectly aligns with management's claim of having over two and a half years of runway, proving that the aggressive operational restructuring executed in late 2025 has successfully stabilized the balance sheet.
Reversing compared to a year ago ($14.1M loss in 25Q1), but stabilizing sequentially ($29.1M loss in 25Q4). The YoY expansion of the net loss is entirely driven by the $27.3M drop in revenue, partially offset by a $15.2M reduction in total operating expenses.
Guidance
Stable. The company maintained its guidance that current cash will fund operations for more than two and a half years. This implies an average quarterly cash burn of roughly $20M-$23M moving forward, entirely consistent with Q1 2026 actuals.
Decelerating timeline. Previous commentary targeted regulatory alignment in H1 2026. The shift to H2 2026 indicates the FDA requires more exploratory dose-optimization data before blessing a pivotal pediatric trial design.
Key Questions
ARCT-032 Data Timing
With the 12-week ARCT-032 Phase 2 study initiating earlier than expected in Q1, when should investors expect the first interim readouts for ppFEV1 and LCI data from this cohort?
ARCT-810 Exploratory Data Needs
Regarding the recent Type C meeting for ARCT-810, what specific exploratory data did the FDA request to establish the optimal dose, and how many additional patients will need to be dosed before the H2 2026 EOP2 meeting?
Future of the CSL Partnership
With collaboration revenue dropping to $0.6M, what is the current status of the active discussions with CSL regarding the KOSTAIVE vaccine, and should investors model any milestone payments for the remainder of 2026?